| Basics |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
|
| IPO Date: |
May 28, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$39.91B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.63 | 2.21%
|
| Avg Daily Range (30 D): |
$4.96 | 1.82%
|
| Avg Daily Range (90 D): |
$5.58 | 2.18%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.54M |
| Avg Daily Volume (30 D): |
.81M |
| Avg Daily Volume (90 D): |
.76M |
| Trade Size |
| Avg Trade Size (Sh.): |
81 |
| Avg Trade Size (Sh.) (30 D): |
37 |
| Avg Trade Size (Sh.) (90 D): |
37 |
| Institutional Trades |
| Total Inst.Trades: |
10,156 |
| Avg Inst. Trade: |
$6.29M |
| Avg Inst. Trade (30 D): |
$15.27M |
| Avg Inst. Trade (90 D): |
$14.16M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$10.98M |
| Avg Closing Trade (30 D): |
$40.82M |
| Avg Closing Trade (90 D): |
$34.86M |
| Avg Closing Volume: |
79.73K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-2.09
|
$-.44
|
$-.65
|
|
Diluted EPS
|
$-2.09
|
$-.44
|
$-.65
|
|
Revenue
|
$ 2.35B
|
$ 594.19M
|
$ 593.17M
|
|
Gross Profit
|
$ 2.03B
|
$ 524.01M
|
$ 490.52M
|
|
Net Income / Loss
|
$ -269.7M
|
$ -57.48M
|
$ -83.76M
|
|
Operating Income / Loss
|
$ -115.37M
|
$ 18.08M
|
$ -105.16M
|
|
Cost of Revenue
|
$ 322.08M
|
$ 70.18M
|
$ 102.65M
|
|
Net Cash Flow
|
$ 337.53M
|
$ 53.6M
|
$ -133.85M
|
|
PE Ratio
|
|
|
|
|
|
|
